ERGOMED is a clinical development company providing consultancy and full clinical trial related services. ERGOMED can also invest in co-development partnerships thus sharing the risks and rewards of clinical development.
ERGOMED has its headquarters in Frankfurt and ten regional offices in Guildford, Cambridge, Moscow, Zagreb, Novi Sad, Krakow, Madrid, San Antonio (USA), Geneva and Dubai. ERGOMED conducts operations throughout Europe and North America with a special focus on Central and Eastern European countries and the MENA (Middle East and North Africa) region.
ERGOMED has experience in all stages of clinical trials from Phase I to Phase IV and specializes in the fields of Oncology/Hematology and Neurology, with added strengths in Endocrinology, Immunology/Allergy and Neuropathic Pain while retaining experience in many other therapeutic areas and indications. ERGOMED has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies and other targeted agents, cancer vaccines, immunotherapy, radioactive agents, and photodynamic therapies.
ERGOMED can assist with strategic clinical development planning, individual study design, project management and monitoring, study site management, drug safety monitoring and pharmacovigilance, medical writing as well as data management, biostatistics, regulatory assistance and other relevant services. In addition, ERGOMED has access to its own Phase I unit for healthy volunteer studies as well as those in special populations and early phase oncology studies. ERGOMED can also provide post-marketing services such as Phase IV/observational studies, pharmacovigilance, and medical affairs.
ERGOMED has a track record of delivering extremely high quality data within agreed budgets and timelines. As a result a significant portion of ongoing trials come from repeat business from satisfied clients and through referrals from existing customers.
ERGOMED provides services to some of the world’s largest pharmaceutical companies as well as to many small and mid sized drug development companies and has been responsible for the pivotal studies of several drugs including a number of oncology treatments which have gone on to receive European regulatory approval. While ERGOMED prides itself on providing services across the spectrum of the pharmaceutical industry, the company has particular experience in working with biotech. ERGOMED is, therefore, well placed to partner with emerging and developing companies in this sector.
Keys to Our Success
Unique Study Site Coordination model
Therapeutic Expertise
Local market intelligence
Rescue of Failing Programs
Dedicated, Qualified and Long Serving Clinical Operations Staff
High levels of repeat business